OSE Immunotherapeutics – executive interview

In this interview, Silvia Comis MD, chief clinical and medical research officer at OSE Immunotherapeutics, covers the company’s lead immuno-oncology candidate, Tedopi. She outlines the current unmet need in non-small cell lung cancer, as well as Tedopi’s clinical track record to date. She also discusses the ongoing registrational Phase III ARTEMIA programme, alongside several other Phase II programmes in different indications run by various academic groups. She concludes by highlighting the key upcoming catalysts and milestones that investors should watch out for.

OSE Immunotherapeutics is a French clinical-stage biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and immuno-inflammation. Lusvertikimab successfully completed a Phase II trial in late 2024, meeting the primary endpoint with statistical significance and laying a robust foundation for further clinical development efforts. Under OSE’s renewed growth strategy, lusvertikimab remains one of the company’s top strategic priorities and management is committed to advancing its development responsibly.